("
Grant of Share Options
|
Director |
Number of Options Granted |
Exercise Price |
|
|
1,000,000 |
|
|
|
1,000,000 |
|
|
|
500,000 |
|
The Options (which are subject to malus and clawback provisions) will vest after three years following publication of the Company's annual results for 2027 and will be exercisable within 7 years of vesting. Vesting is conditional on the achievement of certain performance criteria which include a total shareholder return and earnings per share measurement.
Further detail is provided below in accordance with Article 19.3 of the EU Market Abuse Regulation.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
|
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
|
|
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
|
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
|
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
|
|
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
|
||||
|
|
|
|
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
|
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Chair |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
|
|
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
|
||||
|
|
|
|
||||
For further information, please contact:
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the